Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
نویسندگان
چکیده
Competing interests Dr Braun and Dr Sieper have held consultancies and received research honoraria, speaker’s honoraria and grants/research support from Centocor, Schering-Plough, Essex Pharma, Wyeth and Abbott. Dr Zeidler has received speaker’s honoraria from Essex Pharma. Dr Burmester has held consultancies for Centocor, Essex Pharma, Wyeth and Abbott; has received honoraria from Centocor, Essex Pharma, Wyeth and Abbott; has been a member of a speaker’s bureau for Centocor, Essex Pharma, Wyeth and Abbott; and has received grants/research support from Centocor, Essex Pharma and Abbott. The other authors declare no conflicts of interest.
منابع مشابه
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
We analyzed the clinical response and the time to relapse after discontinuation of continuous long-term infliximab therapy in patients with ankylosing spondylitis (AS). After 3 years of infliximab therapy, all AS patients (n = 42) discontinued treatment (time point (TP)1) and were visited regularly for 1 year in order to assess the time to relapse (TP2). Relapse was defined as an increase to a ...
متن کاملReparative radiological changes of hip joint after TNF inhibitors in ankylosing spondylitis
Background: Hip involvement in ankylosing spondylitis (AS) is a common extraspinal arthritic manifestation, which is associated to a worse functional outcome. Little data are available on the effectiveness of conservative treatment strategies. The TNF inhibitors have been proven effective on AS activity parameters. Their structural effect on hip disease however, little is studied. Case pres...
متن کاملAnti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA.
OBJECTIVES To estimate efficacy, safety and adherence to therapy of ankylosing spondlitis (AS) patients included in the Czech National Registry ATTRA, and to look for predictive factors for therapy discontinuation. METHODS Patients were included according to the guidelines of the Czech Society for Rheumatology, which involve failure of previous therapy, BASDAI >4, and CRP >10 mg/l. Only patie...
متن کاملCoincidence of Sarcoidosis With Ankylosing Spondylitis in a 48-Year-Old Woman; A Therapeutic Challenge
Introduction: A case of pulmonary sarcoidosis is reported because of difficulties in diagnosis and treatment, including the co-existence of ankylosing spondylitis (AS) and severe corticosteroid dependence. Case Presentation: A 48-year-old nonsmoking woman referred to the hospital because of chronic nonproductive cough and dyspnea with a 10-year history of...
متن کاملEffectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
INTRODUCTION Tumor necrosis factor (TNF) antagonists reduce the signs and symptoms of spondyloarthritides, including ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Our objective was to evaluate the effectiveness and safety of adalimumab, 40 mg every other week, for patients with AS or PsA and prior treatment with infliximab (IFX) and/or etanercept (ETN). METHODS Both trials were 1...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Arthritis Research & Therapy
دوره 7 شماره
صفحات -
تاریخ انتشار 2005